Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2025-12-29 @ 5:47 PM
Study NCT ID:
NCT05878028
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2023-05-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Sponsor:
Organization: